Other Publications Including ORADE Reports
Effective April 2017, ORADE reports will be published on our online newsletter: https://newsletter.ontariorheum.ca/
Please note that the content of each report reflects the opinions and perceptions of the author(s) and not the Ontario Rheumatology Association.
ORA Position Statement on Biosimilars
The ORA has endorsed the CRA position statement on biosimilars. A copy of this position statement is available via this link: CRA Position Statement
ORA and OPA Collaboration - Enhancing Patient Care through the Use of MedsCheck
The ORA Models of Care Committee and the Ontario Pharmacists Association have partnered together to strengthen inter-professional communication and collaboration to enhance and optimize the quality of care for their patients.
ORA/OPA Communication piece may be found here.
Models of Care - May 2014
The Models of Care Committee has identified several key initiatives to help to support the Ontario Framework.
- Download Paper: Models of Care (PDF)
ORA Subsequent Entry Biologic Position Paper - December 17, 2012
The term Subsequent-Entry Biologic (SEB) is used by Health Canada to describe "a biologic product that is similar to and would enter the market subsequent to an approved innovator biologic product." The agency is currently considering the regulatory process by which such products would be granted a marketing licence in Canada. The Ontario Rheumatology Association has released its position paper: Subsequent Entry Biologics (available in DOCX format). For further information, contact firstname.lastname@example.org
- Download Paper: Subsequent Entry Biologics (DOCX)